Prevention of coagulase-negative staphylococcal central venous catheter-related infection using urokinase rinses: a randomised double-blind controlled trial in patients with haematological malignancies

ISRCTN ISRCTN72245261
DOI https://doi.org/10.1186/ISRCTN72245261
Secondary identifying numbers N/A
Submission date
07/03/2007
Registration date
07/03/2007
Last edited
21/01/2008
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Infections and Infestations
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data

Plain English summary of protocol

Not provided at time of registration

Contact information

Dr M V Huisman
Scientific

Leiden University Medical Centre (LUMC)
Department of General Internal Medicine, C2-R
P.O. Box 9600
Leiden
2300 RC
Netherlands

Phone +31 (0)71 625 9111
Email m.v.huisman@lumc.nl

Study information

Study designRandomised, placebo controlled, parallel group, double blinded trial
Primary study designInterventional
Secondary study designRandomised controlled trial
Study setting(s)Not specified
Study typeTreatment
Scientific title
Study objectivesUrokinase rinses will lead to less Coagulase-Negative Staphylococcal (CoNS) infections in patients with haematological malignancies and central vein catheters.
Ethics approval(s)Ethics approval received from the local medical ethics committee
Health condition(s) or problem(s) studiedCoagulase-negative staphylococcal central venous catheter-related infection
InterventionUrokinase rinses of central vein catheter three times weekly (25,000 IU, 5 ml of 5,000 IU/ml).
Intervention typeDrug
Pharmaceutical study type(s)
PhaseNot Specified
Drug / device / biological / vaccine name(s)Urokinase
Primary outcome measureThe main endpoints of the study were the occurrence of any Central Venous Catheter (CVC)-related infection by CoNS. According to previously described criteria these infections were classified as local CVC related infection (insertion site infection or significant CVC colonisation) and systemic CVC­related infections.
Secondary outcome measuresSecondary endpoints in this study were:
1. CVC-related infections caused by other microbial pathogens
2. Premature CVC removal
3. Secondary CVC-related complications (metastatic infection, CVC-related thrombosis)
4. Non-CVC related septicaemia bleeding
5. Death
Overall study start date01/01/1996
Completion date01/02/1999

Eligibility

Participant type(s)Patient
Age groupAdult
Lower age limit18 Years
SexNot Specified
Target number of participants161
Key inclusion criteria1. Age of 18 years or older
2. Admission to undergo intensive cytotoxic treatment associated with disruption of the mucosa and deep granulocytopenia (Polymorphonuclear cells [PMNs] less than 0.1 x 10^9/L) for at least 14 days
Key exclusion criteria1. Patients with pre-existing bleeding disorders
2. Patients treated with intravenous unfractionated heparin to prevent veno-occlusive disease
3. Patients with documented septicaemia prior to the start of the study
Date of first enrolment01/01/1996
Date of final enrolment01/02/1999

Locations

Countries of recruitment

  • Netherlands

Study participating centre

Leiden University Medical Centre (LUMC)
Leiden
2300 RC
Netherlands

Sponsor information

Leiden University Medical Centre (LUMC) (The Netherlands)
Hospital/treatment centre

Department of Haematology
P.O. Box 9600
Leiden
2300 RC
Netherlands

Website http://www.lumc.nl/english/start_english.html
ROR logo "ROR" https://ror.org/027bh9e22

Funders

Funder type

Hospital/treatment centre

Leiden University Medical Centre (LUMC) (The Netherlands)

No information available

Results and Publications

Intention to publish date
Individual participant data (IPD) Intention to shareNo
IPD sharing plan summaryNot provided at time of registration
Publication and dissemination planNot provided at time of registration
IPD sharing plan

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?
Results article Results 20/01/2008 Yes No